Clinical results regarding the serum levels and roles of IL-33 in systemic lupus erythematosus (SLE) patients are conflicting [182], possibly due to issues of detection efficacy related to the heterogeneity of SLE patient cohorts in terms of disease activity and stage, treatment, and genetic background. This evidence concerns the gene IL33 and systemic lupus erythematosus.